Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient.

Journal of clinical immunology - 1 Nov 2020

Wegehaupt Oliver, Muckenhaupt Tina, Johnson Matthew B, Schwab Karl Otfried, Speckmann Carsten

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diagnostic Imaging
Share to Disease Susceptibility
Share to Gain of Function Mutation
Share to Lymphoproliferative Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 32944850
DOI: 10.1007/s10875-020-00864-w
PMCID: PMC7567728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient.PMID 32944850Read ↗

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient.Semantic proximity Read ↗

Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.Semantic proximity Read ↗

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.Semantic proximity Read ↗

Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant negative STAT3 mutationsSemantic proximity Read ↗

Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.Semantic proximity Read ↗

Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.Semantic proximity Read ↗

Patients with STAT1 gain-of-function mutations display increased IFNα-induced T cell apoptosis and upregulation of interferon signature that are responsive to ruxolitinib treatment.Semantic proximity Read ↗

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signalingSemantic proximity Read ↗

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal DiseaseSemantic proximity Read ↗

Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function MutationSemantic proximity Read ↗

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.